Eli Lilly and Co. reported a surge in fourth-quarter profit and revenue, driven by robust sales of its diabetes and obesity medications, Mounjaro and Zepbound. While sales fell short of Wall Street expectations, the company maintained its forecast for continued growth in 2025.
Wind and water are slowly taking this luxury house overlooking Cape Cod BayWHO chief asks countries to push Washington to reconsider its withdrawalUS officials advise travelers to be careful in Uganda because of EbolaRise in diagnoses is prompting more US adults to ask: 'Do I have ADHD?'Google scraps its diversity hiring goals as it complies with Trump's new government contractor rulesWith Oscar-nominee 'Conclave' piquing interest, pope keeps dean of the College of Cardinals...
Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36% to $1.55 billion. Overall, Lilly’s quarterly profit swelled to $4.41 billion. Revenue advanced 45% to $13.53 billion, in line with expectations. Per-share earnings adjusted for one-time items totaled $5.32, easily topping the $5.01 that Wall Street was looking for, according to a poll of industry analysts by FactSet.
Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount of weight people lose while taking the injections. They compete withWall Street rises to turn a dismal week into just a bad oneFor 2024, Mounjaro sales more than doubled to $11.54 billion, while Zepbound notched sales of $4.9 billion in its first full year on the market.
Analysts expect more than $18 billion in sales from Mounjaro this year and over $10 billion from Zepbound, which was recently approved in the United States as a treatment for some forms of sleep apnea.For 2025, the Indianapolis drugmaker expects adjusted earnings to range between $22.50 and $24 with revenue falling between $58 billion and $61 billion.Eli Lilly and Co. shares climbed about 2% Thursday morning to $857.40 while broader trading indexes started the day mixed.
HEALTHCARE PHARMACEUTICALS SALES PROFITS INVESTMENT
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly Posts Solid Q4 Earnings Fueled by Diabetes and Obesity Drug SalesEli Lilly and Co. reported strong fourth-quarter earnings, driven by the success of its diabetes and obesity medications, Mounjaro and Zepbound. While sales fell short of some analysts' expectations, the company's overall performance exceeded forecasts, with revenue surging 45% and profits reaching $4.41 billion.
Read more »
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soarsThe results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Read more »
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall shortZepbound and Mounjaro have now underperformed expectations for two straight quarters.
Read more »
Eli Lilly Stock Underperforms Despite Obesity Drug WinsEli Lilly's stock price has declined despite positive news about its obesity drug, Zepbound, which outperformed Wegovy in a head-to-head study. Analysts attribute the stock's underperformance to concerns about upcoming fourth-quarter earnings.
Read more »
Medicare Now Covers Eli Lilly's Obesity Drug Zepbound for Sleep ApneaMedicare Part D plans can now cover Eli Lilly's obesity drug Zepbound for patients with obstructive sleep apnea, expanding its accessibility.
Read more »
Medicare to Cover Eli Lilly's Obesity Drug Zepbound for Sleep ApneaMedicare Part D plans can now cover Eli Lilly's obesity drug Zepbound for patients with obstructive sleep apnea (OSA), expanding access to the medication. This coverage decision follows the FDA's recent approval of Zepbound for treating both obesity and moderate-to-severe OSA.
Read more »